Business
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression
About this update from Immix Biopharma, Inc.
[{"type":"text","content":" 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapyClass-Leading Response Rate in BCMA-exposed patients (frequently excluded from BCMA CAR-T clinical trials) has the potential to meet an important market needImmixBio plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201The expected primary endpoints for NXC-201 in relapsed/refractory multiple myeloma are overall response rate and duration of response LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. The updated dataset consists of 63 multiple myeloma patients (including data on 13 new patients and continued follow-up data on 50 previously enrolled patients), at a poster presentation at the 20th International Myeloma Society Annual Meeting in Athens, Greece on September 27-30, 2023 (72 patient count includes 9 AL Amyloidosis patients which will be announced separately). \"We continue to be very encouraged by NXC-201 clinical results,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “We feel these overall response rate data are compelling as 72% was the overall response rate reported for ABECMA from its pivotal 100-patient KarMMa trial in relapsed/refractory multiple myeloma. Additionally, we believe NXC-201 has demonstrated promise in the rapidly growing segment of BCMA-exposed relapsed/refractory multiple myeloma patients who are frequently excluded from CAR-T clinical trials.” Updated clinical data in 63 patients from the ongoing NEXICART-1 (NCT04720313) study of NXC-201 for the treatment of relapsed/refractory multiple myeloma are as of the July 17, 2023 data cut-off. Median foll...